Skip to main content
. Author manuscript; available in PMC: 2009 Sep 18.
Published in final edited form as: Pharm Res. 2007 Mar 22;24(6):1217–1224. doi: 10.1007/s11095-007-9253-0

Fig. 6.

Fig. 6

In vivo degradation of L-PG-NIR813. A: Representative whole-body NIRF images acquired at the indicated times after intravenous injection of L-PG-NIR813 at a dose of 10 nmol eq. NIR813 per mouse. The activity seen in intact animals primarily arose from the liver and the gut. B: Representative NIRF images of excised tissues at 4 h after conjugate injection. C: Distribution of fluorescence signals in various tissues at 4 h after injection of L-PG-NIR813 or D-PG-NIR813. The data represent mean ± SD (n = 3) (*, p < 0.05; **, p < 0.005).